NextCell Pharma Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de NextCell Pharma.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	46.0%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Here's Why We're Not Too Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Situation

May 31

We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully

Feb 15

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como NextCell Pharma no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

OM:NXTCL - Estimaciones futuras de los analistas y datos financieros pasados (SEK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
5/31/2024	14	-37	-43	-43	N/A
2/29/2024	15	-39	-48	-46	N/A
11/30/2023	16	-41	-49	-45	N/A
8/31/2023	14	-40	-48	-44	N/A
5/31/2023	11	-40	-45	-33	N/A
2/28/2023	9	-38	-41	-32	N/A
11/30/2022	8	-37	-44	-36	N/A
8/31/2022	6	-35	-41	-33	N/A
5/31/2022	6	-30	-37	-37	N/A
2/28/2022	6	-28	-33	-33	N/A
11/30/2021	5	-26	-27	-26	N/A
8/31/2021	4	-25	-26	-26	N/A
5/31/2021	4	-25	-26	-25	N/A
2/28/2021	4	-23	-23	-23	N/A
11/30/2020	4	-19	-21	-20	N/A
8/31/2020	4	-18	-20	-19	N/A
5/31/2020	4	-17	-18	-16	N/A
2/29/2020	4	-17	-18	-17	N/A
11/30/2019	3	-16	-16	-16	N/A
8/31/2019	2	-18	-19	-19	N/A
5/31/2019	2	-17	-21	-21	N/A
2/28/2019	1	-15	-17	-17	N/A
11/30/2018	1	-16	-17	-17	N/A
8/31/2018	1	-14	-14	-14	N/A
5/31/2018	1	-15	-15	-15	N/A
2/28/2018	1	-16	N/A	-17	N/A
11/30/2017	1	-14	N/A	-15	N/A
8/31/2017	1	-13	N/A	-15	N/A
5/31/2017	1	-11	N/A	-11	N/A
2/28/2017	1	-10	N/A	-10	N/A
11/30/2016	1	-11	N/A	-11	N/A
8/31/2016	1	-11	N/A	-11	N/A
8/31/2015	0	-7	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de NXTCL es superior a la tasa de ahorro (1.1%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de NXTCL crezcan más rápidamente que el mercado Swedish

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de NXTCL crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de NXTCL crezcan más rápidamente que el mercado de Swedish.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de NXTCL crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de NXTCL se prevé que sea elevada dentro de 3 años.

NextCell Pharma Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

NextCell Pharma AB Announces Drug Candidate ProTrans Highlighting in Dagens Medicin's Latest Edition Featuring Ongoing Research Advances in the Treatment of Type 1 Diabetes

NextCell Pharma AB Announces the First Children Have Been Treated in the Young Age Group of the ProTrans-Young Study

NextCell Pharma AB Presents New Long-Term Clinical Data at the International Society for Cell and Gene Therapy 2024 Regional Meeting

Third quarter 2024 earnings released

New major risk - Shareholder dilution

Nextcell Pharma AB Receives Positive Recommendation from Data Safety Monitoring Board for Protrans-Young Study

Nextcell Pharma AB Elects Hans-Peter Ekre as New Chairman of the Board

Second quarter 2024 earnings released

NextCell Pharma AB Announces Swedish Health and Social Care Inspectorate Grants Their Cellaviva Tissue Establishment Permission to Handle Amniotic Tissue

NextCell Pharma AB, Annual General Meeting, Nov 28, 2024

Anders Essen-Möller Resigns as Chairman of NextCell Pharma AB

The Swedish Medical Products Agency Approves Subgroup Analysis in NextCell Pharma AB's ProTrans-Young study

New minor risk - Share price stability

First quarter 2024 earnings released

Nextcell Pharma Announces Updates Regarding Nextcell's Clinical Trials with Protrans

Full year 2023 earnings released

NextCell Pharma AB to Report Fiscal Year 2024 Results on Oct 24, 2024

Third quarter 2023 earnings released

NextCell Pharma AB Announces Treatment Start of Severe Pneumonia with High Dose of ProTrans

New minor risk - Share price stability

Second quarter 2023 earnings released

We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully

First quarter 2023 earnings released

NextCell Pharma AB to Report Fiscal Year 2023 Final Results on Nov 09, 2023

NextCell Pharma AB Announces First Pediatric Patients Treated with ProTrans in Type-1 Diabetes Phase II Study

Less than half of directors are independent

Full year 2022 earnings released

Nextcell Pharma AB Announces Trial with Protrans Gets Green Light for Phase Ii Part

Nextcell Cell Therapy Shows Long-Term Effect in Two Independent Diabetes Studies "ProTrans-Repeat" and "ProTrans-Obs"- Live Presentation

Nextcell Pharma AB Announces Protrans Cell Therapy Provides Long-Term Effect in Type-1 Diabetes with A Single Treatment

NextCell Pharma AB Announces Type-1 Diabetes Patients Receiving Two Treatments with A High Dose of Protrans Cell Therapy

We're Not Very Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Rate

NextCell Pharma AB Announces ProTrans Cell Therapy to Be Granted Patent Protection Beyond Europe

Third quarter 2022 earnings released

NextCell Pharma AB Announces Patients in the First Part of Pediatric Diabetes Trial with Nextcell's Protrans Treated

The European Patent Office intends to grant a Patent to NextCell Pharma AB for Selection Algorithm

NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans

Second quarter 2022 earnings released

Less than half of directors are independent

NextCell Pharma AB Announces First Age Group Treated in Paediatric Diabetes Study with Protrans

NextCell Pharma AB Announces Clinical Trial ProTrans19+CA Expanded to Include an Additional Site: The Jewish General Hospital In Montreal, Canada

NextCell Pharma AB Announces Pediatric Diabetes Study with ProTrans in Progress

NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans

First quarter 2022 earnings: Revenues in line with analyst expectations

NextCell Pharma AB to Report Fiscal Year 2022 Final Results on Nov 03, 2022

Director recently bought kr61k worth of stock

We Think NextCell Pharma (STO:NXTCL) Can Afford To Drive Business Growth

Third quarter 2021 earnings released

NextCell Pharma AB Announces COVID-19 Patient Treated with ProTrans

Here's Why We're Not Too Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Situation

NextCell Presents Their Latest Phase II Clinical Data at ISCT 2021

NextCell Pharma AB Announces That Both the Canadian and Swedish Covid-19 Studies Have Been Initiated and Are Now Ready to Include Patients with Severe Pneumonia Triggered by Sars-Cov-2 Infection

Nextcelpharmama AB Recruitments Start for the Protrans Study for Treatment of Covid-19

Second quarter 2021 earnings released

New 90-day low: kr15.30

We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully

NextCell Pharma AB Announces Canadian Trial for ProTrans in COVID-19

First quarter 2021 earnings released: kr0.23 loss per share (vs kr0.20 loss in 1Q 2020)

New 90-day low: kr16.15

NextCell Pharma AB, Annual General Meeting, Nov 24, 2021

New 90-day low: kr16.80

Nextcell Pharma AB Announces Observational Study, Protrans-Obs, receives Approval by the Swedish Ethical Review Board

New 90-day low: kr18.30

NextCell Pharma AB Supports ProTrans Study for Children and Adolescents

Nextcell Starts Eurostars Funded Project Bioscale

Full year earnings released - kr0.92 loss per share

New 90-day high: kr23.80

New 90-day high - kr19.40

NextCell Pharma AB to Report Fiscal Year 2020 Final Results on Nov 12, 2020

New 90-day high - kr13.30

NextCell Pharma AB has completed a Follow-on Equity Offering in the amount of SEK 25.100028 million.

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura